Get Up to Speed on Kawasaki Disease
Kawasaki Disease is a medium vessel vasculitis that typically presents as an acute, self-limited febrile disease. Prompt diagnosis and treatment lead to improved cardiac outcomes for patients. This session will review background information and updated guidelines and recommendations from the American College of Rheumatology and Vasculitis Foundation for the treatment of Kawasaki disease, enabling pharmacists to actively participate in patient care discussions.
At the completion of this activity, the participant should be able to:
- Explain the pathophysiology and diagnosis of Kawasaki Disease
- Provide evidence-based treatment recommendations for patients initially presenting with Kawasaki Disease
- Evaluate the treatment approaches for complex and refractory cases of Kawasaki Disease
Anne Balogh, PharmD, is a PGY1 Pharmacy Resident at Baystate Medical Center. She earned her PharmD at the University of Michigan College of Pharmacy in 2022. Her practice interests include pediatrics and emergency medicine.
Course Fee: Free for MCPHS alumni, full-time staff, and for all other professionals.
Release Date: June 8, 2023
Expiration Date: June 8, 2024
ACPE UAN: 0026-0000-23-011-H01-P | Knowledge
ACPE Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0 (0.1 CEU)
After registering or logging into mcphsce.org, you can view CE modules in our library.
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 1.0 contact hours (0.1 CEUs).
To receive credit, participants must complete pre and post-assessments, view the entire presentation, and evaluate the session. Participant credit will be reported to the CPE Monitor upon conclusion. Transcripts may be printed from the CPE Monitor.
The policy of Massachusetts College of Pharmacy and Health Sciences is ensuring balance, independence, objectivity, and scientific rigor in all of its educational activities. Any individuals involved in planning or content creation for a continuing education activity are required to disclose financial relationships with ineligible companies that have occurred within the last 24 months. The intent of the policy is to identify and mitigate potential conflicts of interest that may affect the activity. All clinical medicine recommendations must be based on evidence accepted within the medical profession.
Anne Balogh, PharmD, has no relevant financial relationships with ineligible companies to disclose.
Content Reviewer, Evan Horton, PharmD, BCCPS, has no relevant financial relationships with ineligible companies to disclose.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies related to the content of this presentation.
Massachusetts College of Pharmacy and Health Sciences will identify, review, and mitigate all conflicts of interest disclosed prior to delivery of an educational activity to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but provides participants with information that may be of potential importance when they are evaluating content.